Pretreatment Neutrophil-to-Lymphocyte Ratio and Smoking History as Prognostic Factors in Advanced Non–Small Cell Lung Cancer Patients Treated with Osimertinib

BACKGROUND: The remarkable efficacy of osimertinib in non‒small cell lung cancer (NSCLC) with acquired T790M mutation has been widely documented in clinical trials and real-world practice. However, some patients show primary resistance to this drug. Even patients who initially show a favorable respo...

Descripción completa

Detalles Bibliográficos
Autores principales: Park, Ji Young, Jang, Seung Hun, Lee, Chang Youl, Kim, Taehee, Chung, Soo Jie, Lee, Ye Jin, Kim, Hwan Il, Kim, Joo-Hee, Park, Sunghoon, Hwang, Yong Il, Jung, Ki-Suck
Formato: Online Artículo Texto
Lenguaje:English
Publicado: The Korean Academy of Tuberculosis and Respiratory Diseases 2022
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8987662/
https://www.ncbi.nlm.nih.gov/pubmed/35045686
http://dx.doi.org/10.4046/trd.2021.0139

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8987662/
https://www.ncbi.nlm.nih.gov/pubmed/35045686
http://dx.doi.org/10.4046/trd.2021.0139

Ejemplares similares